Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) EPS (Basic) (2022 - 2025)

Oramed Pharmaceuticals' EPS (Basic) history spans 4 years, with the latest figure at $1.75 for Q4 2025.

  • For Q4 2025, EPS (Basic) changed N/A year-over-year to $1.75; the TTM value through Dec 2025 reached $3.04, changed N/A, while the annual FY2025 figure was $1.53, 418.75% up from the prior year.
  • EPS (Basic) reached $1.75 in Q4 2025 per ORMP's latest filing, up from $1.16 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.75 in Q4 2025 to a low of -$0.48 in Q3 2024.
  • Average EPS (Basic) over 4 years is $0.27, with a median of $0.22 recorded in 2024.
  • Peak YoY movement for EPS (Basic): surged 833.33% in 2024, then crashed 575.0% in 2025.
  • A 4-year view of EPS (Basic) shows it stood at $0.31 in 2022, then increased by 6.45% to $0.33 in 2023, then crashed by 245.45% to -$0.48 in 2024, then surged by 464.58% to $1.75 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EPS (Basic) are $1.75 (Q4 2025), $1.16 (Q3 2025), and $0.32 (Q2 2025).